Judith Anne Shizuru

CIK: 0001883000

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

JSPR

Jasper Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

JSPR
Jasper Therapeutics, Inc.
Jul 31, 2026
Award(A)
Stock Option (Right to Buy
Direct
7.5K shares-
JSPR
Jasper Therapeutics, Inc.
Sep 22, 2025
Purchase(P)
Direct
41K shares at avg. $2.43$100K
JSPR
Jasper Therapeutics, Inc.
Jul 3, 2025
Award(A)
Stock Option (right to buy)
Direct
7.5K shares-

		Type	Shares	Price		Ownership
Jul 31, 2026	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (Right to Buy	7,500	-	-	Direct
Sep 22, 2025	JSPR Jasper Therapeutics, Inc.	Purchase(P)	41,000	$2.43	$99,630	Direct
Jul 3, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	7,500	-	-	Direct

1-3 of 3 transactions

About Shizuru Judith Anne

Shizuru Judith Anne (SEC CIK 0001883000) files insider reports with the SEC as Director of Jasper Therapeutics, Inc. (JSPR).

Signal8 holds 3 ownership filings by Shizuru Judith Anne, all Form 4s, filed between Jul 3, 2025 and Aug 4, 2026. Those filings report 3 transactions, from Jul 3, 2025 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shizuru Judith Anne's filings is in REDWOOD CITY, CA.

Recent filings by Shizuru Judith Anne

Jul 31, 2026: Grant or award of JSPR derivative securities (Form 4, code A).
Sep 22, 2025: Open-market purchase of JSPR shares (Form 4, code P).
Jul 3, 2025: Grant or award of JSPR derivative securities (Form 4, code A).

Other insiders filing for Jasper Therapeutics, Inc. (JSPR)

WIGGANS THOMAS G, Director
Lucas Svetlana, Director
Crutcher Patrick J, Director
EMSTER KURT VON, Director
Keenan Greg, Chief Medical Officer
Ros Matthew E, Chief Operating Officer

How to read Form 4 transaction codes